The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Alcon; Allakos; GlaxoSmithKline; Juno Therapeutics
Travel, Accommodations, Expenses - Philip Morris International
TRANSCEND NHL 001: Health-related quality of life (HRQL) and symptom (Sx) impact in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017).
 
Donald L. Patrick
No Relationships to Disclose
 
Karen C. Chung
Employment - Celgene; Jazz Pharmaceuticals
Stock and Other Ownership Interests - Celgene; Jazz Pharmaceuticals
 
Yeonhee Kim
Employment - Celgene; Gilead Sciences
Stock and Other Ownership Interests - Celgene; Gilead Sciences
 
Jacob Garcia
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Amgen; Celgene
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
Travel, Accommodations, Expenses - Celgene
 
Christine Dehner
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
 
David G. Maloney
Honoraria - Eureka Therapeutics; Genentech; Gilead Sciences; Kite, a Gilead company; Novartis
Research Funding - Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers and Uses Thereof for Selecting Immunotherapy Intervention (Inst); Methods and Compositions Related to Toxicity Associated with Cell Therapy (Inst); Methods for Adoptive Cell Therapy Targeting ROR1 (Inst); Methods for the Treatment of B Cell Malignancies Using Adoptive Cell Therapy (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics